Cover Image

歐盟5國的MA (醫療事務) 部門的評估:HIV

Medical Affairs Reputations: HIV (EU5)

出版商 FirstWord 商品編碼 363944
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
歐盟5國的MA (醫療事務) 部門的評估:HIV Medical Affairs Reputations: HIV (EU5)
出版日期: 2016年05月01日 內容資訊: 英文

本報告提供HIV治療藥的主要8產品的各公司醫療事務 (MA) 團隊的歐盟5國的150名感染疾病專門醫生的調查,對各公司隊的效能及滿意度的評分及排行榜,醫生的服務利用趨勢,要求,改進點等分析彙整


  • Celsentri (maraviroc; ViiV Healthcare)
  • Evotaz (atazanavir/cobicistat; BMS/Gilead)
  • Intelence (etravirine; Janssen Cilag)
  • Isentress (raltegravir; Merck, Sharpe & Dohme)
  • Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Viread (tenofovir disoproxil fumarate; Gilead)


  • MA團隊的利用方法、頻率
  • 認為最重要的服務
  • 聯繫的頻率和偏好的途徑
  • 對各團隊醫生的印象
  • 各團隊的效能、滿意度排行榜:12項
  • 醫生的需求與服務的改進點等
Product Code: 596200666

HIV: Hard work is paying off for the top 2 medical affairs teams in Europe. How is your team doing?

In the past 6 months, the medical affairs teams for two leading HIV treatments reached up to 91% of the doctors we surveyed-and earned top marks for delivering the services doctors want most.

No wonder their overall satisfaction scores are up to one and a half times that of their closest rival.

See how your team compares in Medical Affairs Reputations: HIV.

You'll learn how infectious disease specialists rate the teams for 8 major HIV treatments, whether they're satisfied with your team's performance, and where your team needs improvement.

Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Interested in the US market?

Answering Key Questions about Medical Affairs Teams for 8 Major HIV Drugs

  • Celsentri (maraviroc; ViiV Healthcare) : Celsentri's team's satisfaction scores are far below average in two areas. Which two?
  • Evotaz (atazanavir/cobicistat; BMS/Gilead) : Evotaz's team and Intelence's team are equally active. Which one has the higher overall satisfaction score?
  • Intelence (etravirine; Janssen Cilag) : What's the one area where Intelence's team earns negative satisfaction scores?
  • Isentress (raltegravir; Merck, Sharpe & Dohme) : Isentress' team outperforms the leading team in several areas. What are they?
  • Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead) : Only two teams have no major areas for improvement. Is Stribild's team one of them?
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare) : In which key area does Triumeq's team get the second lowest satisfaction scores?
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead) : Which team earns higher satisfaction scores for responding promptly to inquiries, Truvada's or Intelence's?
  • Viread (tenofovir disoproxil fumarate; Gilead) : Which team's overall satisfaction score is nearly double Viread's?

Top Takeaways

  • Top 2 brands have a commanding lead: Their teams' overall quality scores are significantly higher than the rest. The same two brands have the leading teams in the US market as well.
  • Activity pays off: Teams that interact more with doctors tend to have higher overall quality scores. The two leading teams have the most interactions by far.
  • Trials and programmes are important: While information provision services tend to rank highest, services related to clinical trials and non-promotional programmes are also important.
  • Doctors prefer face to face: In-person interaction types rank higher than other methods. Even the most popular type of electronic interaction is preferred by less than 50% of doctors.
  • Teams performing well: Performance scores for nearly every team covered are at least moderately high-and highest in the areas important to doctors.
  • Satisfaction varies: Scores range from neutral to high, but the same three teams tend to score highest in almost every area.
  • Clear areas for improvement: Most teams need to improve satisfaction in one or two of the seven medical affairs services most important to doctors.
  • European doctors more likely to prefer frequent interactions: 50% of EU5 doctors prefer to interact with medical affairs teams more than once per quarter compared to 40% in the US.
  • Attitude problems: From better scheduling to spending less time on marketing, doctors identified four separate ways medical affairs teams can improve their "attitude."

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams-answering important questions like:

What do oncologists need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with oncologists?
  • How do oncologists rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to oncologists?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Oncologists

We surveyed 150 infectious disease specialists-30 from each EU5 country (France, Italy, Germany, Spain, UK) , chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with NSCLC in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the last 6 months.

We conducted the survey between April 12th and April 26th, 2016.

Back to Top